(Total Views: 490)
Posted On: 08/14/2025 11:15:24 PM
Post# of 155844
Craig, I know you’re searching so I’ll go ahead and save you the trouble — you’re welcome:
???? Munich Oncology Poster (mTNBC, late-line, heavily pre-treated):
- Objective responses in biomarker-defined patients.
- Clear correlation with CCR5 axis modulation and tumor microenvironment shift.
???? Barcelona Oncology Poster:
- Consistent signal in different cohort.
- Immune profile changes aligned with anti-tumor activity.
???? Mechanism: CCR5 is a validated target in oncology and neuroinflammation. Leronlimab’s MOA is coherent with observed clinical effects.
Small N ≠ no value. In early trials, it’s the reason you expand — and this is exactly what’s happening. Silence in comms ≠ silence in progress.
If you have *actual* counter-data, drop it. Otherwise, stop recycling vague doubt and let the evidence speak.
???? Munich Oncology Poster (mTNBC, late-line, heavily pre-treated):
- Objective responses in biomarker-defined patients.
- Clear correlation with CCR5 axis modulation and tumor microenvironment shift.
???? Barcelona Oncology Poster:
- Consistent signal in different cohort.
- Immune profile changes aligned with anti-tumor activity.
???? Mechanism: CCR5 is a validated target in oncology and neuroinflammation. Leronlimab’s MOA is coherent with observed clinical effects.
Small N ≠ no value. In early trials, it’s the reason you expand — and this is exactly what’s happening. Silence in comms ≠ silence in progress.
If you have *actual* counter-data, drop it. Otherwise, stop recycling vague doubt and let the evidence speak.
(10)
(1)
